Nature's Great Discovery! Obesity is associated with intestinal flora disorders, and statins can enhance intestinal microflora diversity!

1, 2020 /PRNewswire
BIOON /- In 2012, the European Union Meta Cardis Consortium, a group of 14 multidisciplinary research groups from six European countries, began investigating the potential role of the gut microbiome in the development of heart metabolic diseasesThe project, coordinated by Professor Karine Clement of INSERM, France, examined the phenotypes of heart metabolic diseases (obesity,diabetesand cardiovascular disease) in the healthy state of more than 2,000 Europeansrecently, a team led by Professor Jeroen Raes (VIB-KU Leuven) and Clement (INSERM) published their first findings in the authoritative journal Nature, identifying the common cholesterol-lowering drug statins as a potential microbial-regulating treatmentin a paper entitled "Statin therapy associates with lower with lower perce" and colleagues studied theof gutbacteria in the Metacardis queue, which consists of nearly 900 people from three countries (France, Denmark and Germany) and has a BMI of 18 to 73 kg/m2Although the gut flora of obese individuals has previously been shown to be different from those of thin people, Raes's unique experience in quantitative microbiome analysis has given researchers a new insight into changes in the microbiome associated with obesityPicture: Nature
Professor Jeroen Raes said: "Recently, our laboratory has found a single gut microbiome structure (intestinal phenotype) that increases in patients with intestinal inflammation (inflammatory intestinal disease), multiple sclerosis anddepressionWe observed that the intestinal type of this disorder is characterized by low bacterial abundance and biodiversity, and a clear lack of some anti-inflammatorybacterial such as Faecalibacterium In fact, even in healthy people, we found a gut microbiome called Bacteroides2, which has slightly higher levels of inflammation among carriers Since obesity is known to cause elevated levels of inflammation throughout the body, we suggest that Bact2 will also be more common among obesity study participants "
MetaCardis researchers explored the gut microbiome structure of thin and obese volunteers and found that Bact2 increased with BMI Although only 4 percent of lean and overweight subjects were considered Bact2 carriers, the proportion rose sharply to 19 percent among obese volunteers The same trend was observed in 2,350 participants in the VIB-KU Leuven Flemish intestinal flora project "We found that participants with Bact2 intestinal type had higher levels of systemic inflammation than expected based on their body mass index," said lead author Sara Vieira-Silva, lead author of the Although this study does not allow for inference of causation, our analysis does show that gut bacteria play a role in developing obesity-related co-diseases through persistent inflammation While these key findings confirm our hypothesis, the results we had when we compared participants who received statin stake and did not receive statin stake were completely unexpected "
statins are commonly used to reduce the risk of heart metabolic diseases In addition to lowering cholesterol, statins can also relieve inflammation throughout the patient's body Now, Vieira-Silva and his colleagues have discovered another potential beneficial effect of statins on the gut flora Among obese people, those taking statins (6%) were significantly less likely to develop the intestinal microbiome disorder Bact2 than those who did not take statins ( 19%) -- comparable to those who were not obese (4%) These striking observations were validated not only in the independent Faecalibacterium intestinal flora project data set, but also in another MetaCardis subset of 280 patients with cardiovascular disease Sara Vieira-Silva, , said: "These results suggest that statins may regulate changes in the harmful gut microbiome and maintain inflammation in obese patients There are still several possible explanations for our results On the one hand, by alleviating inflammation in the gut, statin medications may help reduce hostility in the gut environment and allow the development of healthy microbiomes On the other hand, the direct effects of statins on bacterial growth have been shown, which may be beneficial to non-inflammatory bacterial , or may be the basis for the anti-inflammatory effects of statin drugs "For years, microbiome regulation strategies have revolved around dietary interventions, probiotics and probiotics, to introduce or promote the growth of beneficial bacteria Until recently, there was renewed interest in the effects of small molecules and drugs on the colon ecosystem This research will further build on this momentum Professor Jeroen Raes, , said: "The potential beneficial effects of statins on the intestinal flora open up new prospects for disease treatment, especially given that we have linked the Bact2 intestinal flora to several pathology strains of the role played by the intestinal flora "Our findings offer a range of possibilities for the development of new gut microbiomes to regulate drugs "
, although promising, the results reported are based on cross-sectional analysis, rather than studies that follow the treatment schedule." This means that causation cannot be based on these observations, and researchers cannot rule out that unexplained factors may have played a role For example, participants treated with statins may adopt a very healthy lifestyle after being diagnosed
with an increased risk of developing cardiovascular metabolic disease, which may have a profound impact on their intestinal ecosystem Photo Source: Nature "So," the researchers warned, "While our results are certainly promising, further evaluation sits in the of prospective clinical trials to determine whether this effect can be reproduced in randomized populations before considering the use of statins as a microbial regulatory therapy." "
current research is part of a larger effort by the MetaCardis Alliance, sponsored by the European Commission, to shed light on the role of gut microbes in cardiovascular disease Lead researcher Professor Karine Cl?ment, clinical Metacardis, said: "As a key risk factor for heart disease, part of the coalition's research is working to outline a comprehensive blueprint for changes in the gut microbiome associated with obesity More discoveries will be made in the future: MetaCardis is exploring whether and what, in addition to obesity, can lead to further progression of heart metabolic disease The ultimate goal of our study is to clarify the role of gut bacteria in the development of heart disease and, in the long run, to be able to present innovative
diagnostic , prevention, and even therapeutic tools based on the insights of the new microbiome The alliance is currently completing several additional studies, so stay tuned! (biovalleybioon.com) references: Obesity is linked to gut microbiota, but not not in-the-city-sedindividuals
Statin drugs boost healthy gutbes
Statinrapy is is lower withce of the gut microbiota dysbios, Nature (2020) DOI: 10.1038/s41586-020-2269-x